Table 7.
Outcome measures
|
Sample groups
|
Baseline
|
One-month
|
P value
|
Effectiveness size
|
Power
|
Total compassionate score | ||||||
To others | VR (n = 23), mean (SD) | 78.03 (11.65) | 76.26 (9.64) | 0.548 | 0.1611 | 0.0902 |
TAU (n = 17), mean (SD) | 82.86 (8.36) | 80.69 (6.81) | 0.424 | 0.2624 | 0.1201 | |
VR vs TAU1 | - | - | 0.122 | 0.5041 | 0.326 | |
From others | VR (n = 23), mean (SD) | 68.56 (18.65) | 62.36 (15.30) | 0.205 | 0.3464 | 0.2375 |
TAU (n = 17), mean (SD) | 67.62 (24.65) | 73.13 (22.81) | 0.492 | 0.2256 | 0.1014 | |
VR vs TAU1 | - | - | 0.051 | 0.5605 | 0.3824 | |
Compassionate engagement | ||||||
To others | VR (n = 23), mean (SD) | 42.97 (8.65) | 42.21 (6.89) | 0.728 | 0.093 | 0.0632 |
TAU (n = 17), mean (SD) | 46.67 (6.07) | 44.13 (4.21) | 0.177 | 0.4472 | 0.2586 | |
VR vs TAU1 | - | - | 0.331 | 0.3141 | 0.1557 | |
From others | VR (n = 23), mean (SD) | 37.94 (11.92) | 34.65 (9.32) | 0.270 | 0.2965 | 0.1904 |
TAU (n = 17), mean (SD) | 39.14 (14.79) | 42.38 (13.21) | 0.495 | 0.2237 | 0.1005 | |
VR vs TAU1 | - | - | 0.039a | 0.6839 | 0.5344 | |
To others | VR (n = 23), mean (SD) | 35.06 (5.07) | 34.04 (5.05) | 0.375 | 0.1180 | 0.9984 |
TAU (n = 17), mean (SD) | 36.19 (4.34) | 36.56 (4.94) | 0.679 | 0.0694 | 0.9944 | |
VR vs TAU1 | - | - | 0.058 | 0.307 | 0.5373 | |
From others | VR (n = 23), mean (SD) | 30.62 (7.82) | 27.64 (7.31) | 0.138 | 0.199 |
0.9629 |
TAU (n = 17), mean (SD) | 28.48 (10.30) | 30.75 (10.36) | 0.540 | 0.101 | 0.9863 | |
VR vs TAU1 | - | - | 0.156 | 0.232 | 0.8066 |
P < 0.05.
Virtual reality vs treatment as usual comparison at one-month.
VR: Virtual reality; TAU: Treatment as usual.